Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q1 FY24 results · Apr–Jun 2023
Aarti Drugs reported revenue from operations of ₹661.11 crore (up 6.3% from Q1 FY23) and net profit of ₹47.97 crore (up 37.9% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 661.11 | 621.96 | +6.3% | 742.41 | −11.0% |
| Other income | 0.60 | 0.26 | +130.8% | 0.87 | −31.0% |
| Total income | 661.71 | 622.22 | +6.3% | 743.28 | −11.0% |
| Profit before tax | 63.53 | 48.03 | +32.3% | 73.28 | −13.3% |
| Net profit for the period | 47.97 | 34.78 | +37.9% | 56.18 | −14.6% |
| EPS, basic (₹) | 5.18 | 3.76 | +37.8% | 6.07 | −14.7% |
| Net margin (%) | 7.3 | 5.6 | 7.6 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 591.63 | 551.20 | +7.3% | 696.41 | −15.0% |
| Other income | 0.65 | 0.24 | +170.8% | 0.93 | −30.1% |
| Total income | 592.28 | 551.44 | +7.4% | 697.34 | −15.1% |
| Profit before tax | 53.04 | 36.35 | +45.9% | 69.42 | −23.6% |
| Net profit for the period | 39.54 | 26.35 | +50.1% | 53.17 | −25.6% |
| EPS, basic (₹) | 4.27 | 2.85 | +49.8% | 5.74 | −25.6% |
| Net margin (%) | 6.7 | 4.8 | 7.6 |
Consolidated
- Filed with BSE
- 22 Jul 2023, 12:55 IST
- Board meeting
- 21 Jul 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 Jul 2023, 12:55 IST
- Board meeting
- 21 Jul 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Audited
- Source
- XBRL filing on BSE